Pharmaceuticals: Why ad spending’s ailing
March 28, 2013
A number of ad categories have increased spending over the past few years following deep declines during the height of the recession.
Pharmaceuticals is not one of them.
Even as positive economic news builds, including a decrease in the unemployment rate, an increase in home building starts and a surge in the stock market, drug companies have reigned in their ad budgets.
Unlike many other categories, such as automotive and retail, pharmaceutical spending is tied not so much to the economy as to the state of the industry itself, and right now the mood is one of extreme caution.
Last year GlaxoKlineSmith reached a $3 billion settlement with the Justice Department over the marketing and development of its drugs. The government accused the British company of, among other things, advertising its drugs to treat ailments they were not approved for.
“Overall the business in the past several years has taken a more cautious approach to marketing in response to fears about regulation,” notes Jon Swallen, chief research officer at Kantar Media North America.
No one wants to be the next GlaxoKlineSmith, and in response many companies have pulled back on their advertising.
Last year spending in the category declined 3.8 percent, according to data crunched by Kantar and Nomura, from $7.6 billion to $7.31 billion.
It was the third-biggest decline for any top-20 ad category, behind only office supplies (down 10.3 percent) and media and entertainment (down 4.2 percent).
No individual pharmaceutical advertiser finished among the top 10 for 2012, according to Kantar. Pfizer was among the top seven until 2011.
Pharmaceutical advertising has dropped sharply in magazines as well as spot television, where spending plunged 30 percent last year, according to the TVB.
The other issue holding back spending is that there hasn’t been a major new drug introduction in some years. With no major new drugs to promote, pharmaceutical companies have little reason to increase spending.
In the past, rollouts of drugs such as Viagra, Lipitor and Zoloft have triggered a huge amount of ad spending to familiarize the public with the purpose and benefits of the new medications.
“Part of the reason is there have not been any big blockbuster marketing launches for newly approved drugs,” Swallen says.
“That was traditionally the catalyst during the last half of the past decade, 2005 to 2010. The category was propelled by marketing introductions.”
And with no major introductions on the horizon, the pharmaceutical ad chill could last for years to come.
One screen not enough for Olympics viewers
Meredith chops Ladies’ Home Journal
For magazines, it’s not all bad news
‘American Idol’ grows as Fox wins Wednesday
This month’s new media traffic data
Readers: No C7 during this upfront
Fact: We now use the web more than TV
May’s five biggest sweeps stunts
So tell us, which network will win May sweeps?
‘Relative Insanity,’ totally inane
For NBC’s Thursday, an early close
Cable overnights: New high for ‘Chrisley’
The word: FCC guts net neutrality rules
- Mike Goller becomes group brand director at 72andSunny
- Jack Tarantino and Elvia Van Es Oliva join TLC
- Facebook chief financial officer David Ebersman exiting
- Christopher Mims becomes tech columnist at Wall St. Journal
- Mitzi Miller becomes editor in chief at Ebony magazine
- Jane Keltner de Valle becomes fashion news director at Glamour
- Constance Sayers Witherspoon and Tom Shoop rise at Atlantic Media
- Felix Salmon becomes a senior editor at Fusion
- Chris Rovzar joins Bloomberg to develop new luxury news product
- Francis Pizzani becomes director of sales at Yangaroo
This month’s new media traffic data
This week’s cable ratings
This week’s broadcast ratings
This week’s top movies, songs and books
This week’s daypart ratings
This week’s younger viewer ratings
Senior digital media planner job in L.A.
Media planner position in Dallas
Needed: Senior digital media buyer and planner
Expert marketing consultant available in all markets
Media buyer/planner job in Philadelphia